Ensysce Biosciences (Ensysce Biosciences) Interest Expense : $-1.60 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ensysce Biosciences's interest expense for the three months ended in Mar. 2024 was $ -1.25 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.60 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ensysce Biosciences's Operating Income for the three months ended in Mar. 2024 was $ -1.84 Mil. Ensysce Biosciences's Interest Expense for the three months ended in Mar. 2024 was $ -1.25 Mil. Ensysce Biosciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ensysce Biosciences Interest Expense Historical Data

The historical data trend for Ensysce Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences Interest Expense Chart

Ensysce Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-1.00

-1.30

-0.11

-0.35

Ensysce Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial											-	-	-0.01	-0.35	-1.25

Ensysce Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60 Mil.

Ensysce Biosciences (NAS:ENSC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ensysce Biosciences's Interest Expense for the three months ended in Mar. 2024 was $-1.25 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-1.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.

Ensysce Biosciences's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Ensysce Biosciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ensysce Biosciences (Ensysce Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037

Website

https://www.ensysce.com

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.

Executives

Bob G Gower	director	402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick	director, officer: Chief Executive Officer	110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman	officer: Chief Medical Officer	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch	director	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano	officer: Chief Development Officer	7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett	officer: Chief Commercial Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt	officer: Chief Medical Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey	officer: Chief Financial Officer	4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang	director, 10 percent owner	C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard	officer: Chief Operating Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright	officer: Chief Business Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin	director	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037